Technology
Health
Biotechnology
Oncolytics Biotech
$1.919876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (2.14%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ONCY and other stocks, options, ETFs, and crypto commission-free!
About
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Read More The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Employees
—
Headquarters
Calgary, Alberta
Founded
1998
Market Cap
36.38M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
74.92K
High Today
$1.93
Low Today
$1.90
Open Price
$1.90
Volume
28.35K
52 Week High
$7.92
52 Week Low
$1.60
Collections
Technology
Health
Biotechnology
Medical
Canada
North America
News
Yahoo FinanceMay 3
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep - - Interim data from ongoing AWARE-1 window of opportunity breast cancer study expected in 2H 2019 - CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2019. All dollar amoun...
Price Paid on Robinhood
51% Lower
Right Now
52 Week Low
$1.60
Average Price Paid
$3.88
52 Week High
$7.92
Earnings
-$0.28
-$0.19
-$0.11
-$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 2, Pre-Market